Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 637


Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.

Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung NK, Larson SM.

Nucl Med Biol. 1996 Jan;23(1):1-8.


Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.

Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM.

Cancer. 1997 Dec 15;80(12 Suppl):2591-610.


Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.

Casey JL, Pedley RB, King DJ, Green AJ, Yarranton GT, Begent RH.

Br J Cancer. 1999 Nov;81(6):972-80.


Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.

Behr TM, Sgouros G, Stabin MG, Béhé M, Angerstein C, Blumenthal RD, Apostolidis C, Molinet R, Sharkey RM, Koch L, Goldenberg DM, Becker W.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3031s-3043s.


High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.

Behr TM, Béhé M, Stabin MG, Wehrmann E, Apostolidis C, Molinet R, Strutz F, Fayyazi A, Wieland E, Gratz S, Koch L, Goldenberg DM, Becker W.

Cancer Res. 1999 Jun 1;59(11):2635-43.


Radioimmunotherapy of intracerebral human glioma xenografts with 131I-labeled F(ab')2 fragments of monoclonal antibody Mel-14.

Colapinto EV, Zalutsky MR, Archer GE, Noska MA, Friedman HS, Carrel S, Bigner DD.

Cancer Res. 1990 Mar 15;50(6):1822-7.


Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.

Casey JL, King DJ, Chaplin LC, Haines AM, Pedley RB, Mountain A, Yarranton GT, Begent RH.

Br J Cancer. 1996 Nov;74(9):1397-405.


Phase I clinical evaluation of a new murine monoclonal antibody (Mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas.

Sharkey RM, Goldenberg DM, Vagg R, Pawlyk D, Wong GY, Siegel JA, Murthy S, Levine GM, Izon D, Gascon P, et al.

Cancer. 1994 Feb 1;73(3 Suppl):864-77.


Optimal antibody-radionuclide combinations for clinical radioimmunotherapy: a predictive model based on mouse pharmacokinetics.

Yorke ED, Beaumier PL, Wessels BW, Fritzberg AR, Morgan AC Jr.

Int J Rad Appl Instrum B. 1991;18(8):827-35.


Ablation of human colon carcinoma in nude mice by 131I-labeled monoclonal anti-carcinoembryonic antigen antibody F(ab')2 fragments.

Buchegger F, Pfister C, Fournier K, Prevel F, Schreyer M, Carrel S, Mach JP.

J Clin Invest. 1989 May;83(5):1449-56.


Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate.

Beatty BG, Kuhn JA, Hui TE, Fisher DR, Williams LE, Beatty JD.

Cancer. 1994 Feb 1;73(3 Suppl):958-65.


Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 monoclonal antibody in a human neuroblastoma xenograft nude mouse model.

Ugur O, Scott AM, Kostakoglu L, Hui TE, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta BM, Fisher DR, et al.

Nucl Med Biol. 1995 Jan;22(1):87-93.


Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.

Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.

J Nucl Med. 2004 Feb;45(2):327-37.


Assessment of radiolabeled stabilized F(ab')2 fragments of monoclonal antiferritin in nude mouse model.

Quadri SM, Lai J, Mohammadpour H, Vriesendorp HM, Williams JR.

J Nucl Med. 1993 Dec;34(12):2152-9.


The effect of radioimmunotherapy using murine monoclonal antibody KIS1 on esophageal squamous cell carcinoma-bearing nude mice.

Fujii T, Yamana H, Toh Y, Toh U, Fujita H, Shirouzu K, Morimatsu M.

Surg Today. 1997;27(11):1026-34.


Supplemental Content

Support Center